

INFORMATION DISCLOSURE
CITATION

APPLN. NO.

10/594,436

ATTY. DKT. NO.

1050-4

APPLICANT

YOSHITAKE et al.

FILING DATE

GROUP

September 26, 2006

Not Known

U.S. PATENT DOCUMENTS

EXAMINER
INITIAL

DOCUMENT NUMBER

DATE

NAME

CLASS

SUBCLASS

FILING DATE
IF APPROPRIATE

AR

5,035,899

07/1991

Saeki et al.

BR

CR

DR

ER

FR

GR

FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT

DATE

COUNTRY

CLASS

SUBCLASS

YES

NO

HR

0670718 B1

09/1995

Europe

IR

JR

KR

LR

OTHER DOCUMENTS (including Author, Title, Pertinent pages, Date, etc.)

MR Eisai Inc., ACIPHEX (rabeprazole sodium) delayed-release tablets, 17 pages (08/2003).

NR FDA/Center for Drug Evaluation and Research's Orange Book listings for ACIPHEX (rabeprazole sodium) showing use since August 19, 1998, www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm (04/2007)

OR Eisai Co. Ltd., English translation of "PARIET tablet" package inserts and certificates, 22 pages (1998 and 2001).

PR Eisai Co. Ltd., "Eisai receives European marketing authorization for PARIET (rabeprazole sodium) for Zollinger-Ellison syndrome" Japan Corporate News (JCN) Network, one page (07/2004).

QR Eisai Co. Ltd., "Eisai files application seeking additional indication for PARIET in Japan" Japan Corporate News (JCN) Network, one page (03/2005).

RR Teva Pharmaceutical Industries Ltd., "Teva announces approval of rabeprazole sodium delayed-release tablets" PipelineReview.com, one page (02/2007).

SR

TR

UR

VR

WR

XR

YR

ZR

AAR

BBR

CCR

DDR

EER

*Examiner

/Kevin Orwig/

Date Considered

03/12/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.O./

1260739